Re‐challenging chemotherapy after pembrolizumab in platinum‐refractory urothelial carcinoma

Taizo Uchimoto(Osaka University of Pharmaceutical Sciences), Haruhito Azuma(Osaka University of Pharmaceutical Sciences), Fumihiko Urabe(Jikei University School of Medicine), Kosuke Iwatani(Jikei University School of Medicine), Yusuke Yano(Osaka University of Pharmaceutical Sciences), Wataru Fukuokaya(Jikei University School of Medicine), Keita Nakamori(Osaka University of Pharmaceutical Sciences), Jun Miki(Jikei University School of Medicine), Keiichiro Mori(Jikei University School of Medicine), Kazuki Nishimura(Osaka University of Pharmaceutical Sciences), Kyosuke Nishio(Osaka University of Pharmaceutical Sciences), Takafumi Yanagisawa(Jikei University School of Medicine), Kiyoshi Takahara(Osaka Medical and Pharmaceutical University), Ko Nakamura, Shutaro Yamamoto, Yoshio Ohno(Tokyo Medical University), Teruo Inamoto(Hamamatsu University), Takeshi Hashimoto(Tokyo Medical University), Kazumasa Komura(Kawasaki Medical School), Ryoichi Shiroki(Fujita Health University), Takahiro Kimura(Jikei University School of Medicine), Shin Egawa, Tatsuo Fukushima(Osaka University of Pharmaceutical Sciences), Shunsuke Tsuduki(Jikei University School of Medicine), Takahiro Adachi(Tokyo Medical University), Atsuhiko Yoshizawa(Fujita Health University Hospital)
British Journal of Urology
September 13, 2022
Cited by 10


Related Papers